

## INTERIM REPORT

Period from January – September 2022

Peptonic Medical AB (publ) org nr 556776-3064

([www.spotlightstockmarket.com](http://www.spotlightstockmarket.com), ticker: PMED)

### GROUP

#### 2022 THIRD QUARTER (Jul-Sep)

- Net sales of products KSEK 12 180 (7 234)
- Gross profit KSEK 7 137 (4 492), Gross margin 59% (62%)
- Operating loss KSEK -7 786 (-9 856)
- **Adjusted operation loss excl. non-recurrent charge KSEK -7 286 (-9 856)**
- Loss per share SEK -0,04 (-0,05)

#### 2022 FIRST NINE MONTHS (Jan-Sep)

- Net sales of products KSEK 33 442 (25 948)
- Gross profit KSEK 19 002 (16 061), Gross margin 57% (62%)
- Operating loss KSEK -26 807 (-28 780)
- **Adjusted operation loss excl. non-recurrent charge KSEK -26 307 (-28 780)**
- Loss per share SEK -0,12 (-0,15)

## IMPORTANT EVENTS DURING THE PERIOD

- September 1<sup>st</sup> 2022, the Company announced that a distribution agreement was signed with German Medical Supplies for UAE
- September 2<sup>nd</sup> 2022, the Company announced that the ongoing application for a vestibulitis patent has received a positive opinion from the international review
- September 26<sup>th</sup> 2022, the Company announced that the Company has received information that the Ecocrime Authority (EBM) repeats the request for a corporate fine of SEK 500 thousand.
- September 28<sup>th</sup> 2022, the Company announced that VagiVital® AL Self-Test for amniotic fluid leakage detection is now commercially available for sale in its own online store


## IMPORTANT EVENTS AFTER THE PERIOD

- November 4<sup>th</sup> 2022, the Company announced that the ongoing applications for the intimate wash and for the treatment of fungal infection has received positive statements from the international review

## From the CEO

### Second consecutive quarter with improved result

For the second quarter in a row, results are improved. Key underlying reasons are continued positive sales development of the company's vaginal self-tests to partners in the US and Europe, as well as the work to focus Lunette efforts in fewer markets.



Sales compared to previous quarter are largely unchanged (ca -1.5%) where quarter two also contained a batch order to Orion.

The third quarter result is negatively affected by a reservation of 0.5 MSEK related to a potential penalty the Swedish Ecocrime Authority has announced due to a financing solution in 2019. The penalty aside the bottom line improves 10% compared to previous quarter.

### **Business Unit Medical Consumer – New products are well received**

During the pandemic Peptonic has observed a growing trend where people want to take a greater responsibility for their own health. This by using self-care products. In parallel also reduce pressure on health care systems. An important aspect is then that these self-care products have to be clinically proven.

As a result Peptonic has formed the Business Unit Medical Consumer. The purpose with the unit is to establish a portfolio that enables women to diagnose, treat and prevent vaginal medical conditions with clinically self-care solutions. The acquisition of Israeli CommonSense was an important step to start forming the business unit.

During the quarter Peptonic has presented its patented self-test to detect amniotic leakage during pregnancy at the Swedish Association of Gynecologists annual meeting SFOG. The product was well received as a correlating option does not exist in health care today. During the fall, winter and spring midwives and gynecologists will be educated concerning the benefits and clinical platform related to the product. The self-test to detect amniotic leakage, VagiVital AL, has during the quarter been listed for sales in Swedish digital pharmacies.

The interest from international partners concerning VagiVital AL is significant. New distributor agreements have during the quarter been signed with German Medical Supplies for UAE and InVivo Pharma for Georgia. A renewed distributor agreement with Primalabs concerning Italy, France, Poland, Hungary and Romania has also been signed during the quarter.

Peptonics vaginal self-tests as a whole attract many inquiries from potential international distributors.

The development work to broaden the portfolio in line with the newly set strategy is on going. The clinical study with an adapted version of VagiVital AktivGel for the treatment of vaginal yeast infections is still ongoing at the Karolinska University Hospital. The study is expected to be finalized during 2023. We have also informed the market that the submitted patent application for the adapted gel in this indication has passed international assessment. The same applies to the original gel for the treatment of vestibulitis. The company is currently assessing how this shall be taken to the market in the best way.

Business unit Medical Consumer sales in the quarter equaled 6.9 MSEK. The majority of this sales was from sales of the vaginal self-tests.

### **Business Unit Lifestyle Consumer – Improved Focus gives improved direction**

The company's wholly owned subsidiary Lune Group with its sustainable period products as core business, constitutes Peptonics other more life style oriented business unit.

During the spring a renewed strategy was set where Lune reduces its cost mass and focuses on fewer markets. The objective with the revised strategy is to increase competitiveness in selected markets thereby improving results. Amongst focus markets are Finland, Sweden and Australia. The increased focus has started to pay off and the negative result has started to significantly improve in the quarter.

The improved focus is multi-dimensional. Most of Lune business arises from sustainable period products. The renewed focus also means renewed focus and efforts around these core products. During the quarter Lune's new reusable period panties has been picked up for sales a by a major Finnish retail chain as well as a global Swedish retail chain.

Business unit Lifestyle Consumer sales during the quarter correlates to 5.3 MEK.

### **The new strategy and focus - a foundation for continuous positive development**

Concerning vaginal medical conditions one can, a bit simplified, say that there are prescription products and self-care products. Peptonics objective is to create a new category with **clinically proven** intimate self-care products. The aim is to become a leading player in this category by offering innovative complete solutions that enable diagnose, treatment and prevention of the medical conditions that occur.

With the distinct profile, the attractiveness of the vaginal self-tests as door openers and new innovative products in line with the strategy, Peptonic expects continuously increased distribution in Swedish pharmacies as well with international distributor partners.

With the above as platform the company shall continue broadening the portfolio through a combination of own development, in licensing and acquisitions.

November 10, 2022

Erik Sundquist

CEO

## COMPANY BRIEF

Peptonic Medical AB (publ) is an innovative biomedical company that conducts research on and development of drugs and medical devices in the field of women's health. Our vision is to offer safe and effective treatments for women-specific diseases and medical conditions. Peptonic Medical launched VagiVital® in July 2018. This is a hormone-free product for the treatment of vaginal atrophy and vaginal dryness. See [www.vagivital.com](http://www.vagivital.com)

Since August 2020, Lune Group Oy Ltd. is a wholly owned subsidiary of the Peptonic Medical. Lune Group Oy Ltd. is a company founded by Heli Kurjanen in 2005. The company's business concept is to lead a menstrual revolution in a positive spirit. By focusing on sustainable development, environmental issues and the promotion of sexual health, the company has developed to take the lead for the menopausal companies. Lunette® menstrual cups are an alternative to disposable menstrual protection and last for several years. The company has resellers in 50 countries and sells Lunette products to over 100 countries via its web shop. Lune Group has in the USA the subsidiary Lune North America Inc. Lunette® menstrual cups are designed, manufactured, and packaged in Finland. For more information about Lunette®, visit [www.lunette.com](http://www.lunette.com).

The company was founded in 2009 and the share has been traded since 2014 on Spotlight ([www.spotlightstockmarket.com](http://www.spotlightstockmarket.com)), short code: PMED in Stockholm.

## FINANCIAL INFORMATION

### Group

**Revenue** - Sales of goods during the third quarter amounted to SEK 12 180 (7 234) thousand. Other operating income for the quarter was SEK 187 (-52) thousand. During the first nine months of the year, sales of goods amounted to SEK 33 442 (25 948) thousand. Other operating income for the first nine months of the year was SEK 1 037 (-43) thousand.

**Costs** - Costs for the third quarter amounted to SEK -20 154 (-17 038) thousand. Costs for the first nine months of the year amounted to SEK -61 286 (-54 685) thousand. Costs of goods for the third quarter amounted to SEK -5 043 (-2 742) thousand. Costs of goods for the first nine months of the year amounted to SEK -14 440 (-9 855) thousand. During the third quarter, a reservation regarding corporate fines of KSEK 500 from EBM charged other costs.

**Profit** - The company's profit after net financial items for the third quarter amounted to SEK -8 524 (-9 853) thousand. For the first nine months of the corresponding amount is SEK -28 825 (-28 936) thousand.

**Financial position and liquidity** - Cash and bank amounted to SEK 3 015 (10 009) thousand as of September 30th, 2022. After the end of the quarter, Peptonic Medical AB has used the Covid loan facility at the Swedish Tax Agency, where KSEK 3 600 has been borrowed with a very favorable interest rate. Work on long-term financing has been initiated.

**Shareholders' equity** - The group's shareholders' equity as of September 30, 2022, amounted to SEK 56 919 (72 349) thousand, which gives an equity / assets ratio of 64 (87) percent.

**Liabilities** - The group's liabilities, as of September 30, 2022, amounted to SEK 32 747 (10 576) thousand.

**Organization** - During the period, the average number of employees was 31 (18). At the end of the period, the number of employees was 33 (17).

**Share** - The total number of shares as of September 30, 2022 was 242,743,544 (191,639,642).

**INCOME STATEMENT**

**Peptonic Group**

KSEK	Note	<b>3 mon jul-sep 2022</b>	<b>3 mon jul-sep 2021</b>	<b>9 mon jan-sep 2022</b>	<b>9 mon jan-sep 2021</b>	<b>12 mon jan-dec 2021</b>
<b>Operating income</b>						
Sales of products		12 180	7 234	33 442	25 948	31 643
Other operating income		187	-52	1 037	-43	622
<b>Total operating income</b>		<b>12 368</b>	<b>7 182</b>	<b>34 479</b>	<b>25 904</b>	<b>32 265</b>
<b>Operating expenses</b>						
Cost of goods		-5 043	-2 742	-14 440	-9 887	-12 573
Other external expenses	1	-7 536	-9 122	-26 780	-30 200	-45 690
Personnel costs		-6 081	-4 266	-17 337	-10 501	-19 430
Depreciation		-869	-888	-2 605	-2 644	-27 055
Other operating costs		-625	-20	-123	-1 452	-1 234
<b>Total operating expenses</b>		<b>-20 154</b>	<b>-17 038</b>	<b>-61 286</b>	<b>-54 685</b>	<b>-105 983</b>
<b>Operating loss</b>		<b>-7 786</b>	<b>-9 856</b>	<b>-26 807</b>	<b>-28 780</b>	<b>-73 718</b>
Net financial income/expense		-738	2	-2 019	-141	30
<b>Loss before taxes</b>		<b>-8 524</b>	<b>-9 853</b>	<b>-28 825</b>	<b>-28 921</b>	<b>-73 688</b>
Taxes		0	0	0	-15	0
<b>Net loss for the period</b>		<b>-8 524</b>	<b>-9 853</b>	<b>-28 825</b>	<b>-28 936</b>	<b>-73 688</b>

**BALANCE SHEET**

**Peptonic Group**

KSEK	Note	30-sep 2022	30-sep 2021	31-dec 2021
<b>Assets</b>				
<b>Non-Current assets</b>				
Intangible assets	2	50 447	52 938	52 210
Goodwill/badwill	2	0	0	
Tangible assets	3	4 321	1 333	4 204
Financial assets		0	7	0
<b>Total non-current assets</b>		<b>54 768</b>	<b>54 278</b>	<b>56 413</b>
<b>Current assets</b>				
Stock		17 694	9 403	10 323
On going fund raising		0	0	0
Other receivbles		12 756	8 582	5 166
Tax receivable		0	0	524
Prepaid expenses and accrued income		1 432	652	920
Liquid assets		3 015	10 009	10 153
<b>Total current assets</b>		<b>34 898</b>	<b>28 646</b>	<b>27 086</b>
<b>Total assets</b>		<b>89 666</b>	<b>82 924</b>	<b>83 500</b>
<b>Equity and liabilities</b>				
<b>Equity</b>				
<b>Ristricted equity</b>				
Share capital		24 274	19 254	19 164
Ongoing right issues		0	0	0
Reserves		11 186	11 186	9 617
Other contributed capital		276 157	213 606	247 337
Profit or loss brought forward incl year result		-254 698	-171 698	-224 101
<b>Total equity</b>	3	<b>56 919</b>	<b>72 349</b>	<b>52 017</b>
<b>Current liabilities</b>				
Liabilities interest bearing		9 615	7 606	6 219
Trade payables		16 269	0	15 347
Other payables		992	991	2 885
Prepaid income and accrued expenses		5 872	1 979	7 032
<b>Total current liabilities</b>		<b>32 747</b>	<b>10 576</b>	<b>31 483</b>
<b>Total equity and liabilities</b>	4	<b>89 666</b>	<b>82 925</b>	<b>83 500</b>



## NOTE

### Accounting principles

This interim report has been prepared in accordance with the Annual Accounts Act (Chapter 9. Interim Report) and the Swedish Accounting Standards Board's general advice, BFNAR 2012:1 Annual Report and consolidated (K3-rules).

### Note 1 – Related-party transactions

#### Group/Peptonic Medical AB

During the period companies represented by members of the Board of Directors were contracted as consultants. Total compensation for consultancy services amounted to SEK 513 (1 364) thousand and is related to business development services. All transactions between related parties are based on market conditions. No other key executives or their immediate family members have been directly or indirectly involved in any business transaction with the Company that is or was unusual in its character or terms and conditions and took place during the period.

KSEK	<b>2022</b>	2021	2020
	<b>Jan-Sep</b>	Jan-Sep	Jan-Sep
Consulting fees Board of Directors	513	1364	665
<b>Total</b>	<b>513</b>	<b>1364</b>	<b>665</b>

### Note 2 – Intangible assets (KSEK)

Patent and development costs are capitalized and depreciated in 20 years from the first revenue that the group receives. The depreciations started in year 2019. Capitalized patent and development costs are estimated to result in future revenues for the Group. From 2019 they are depreciated at 5% per annum. Which corresponds to the estimated life of the commercial rights. The group's goodwill is fully written down in 2021. In 2021, costs for the acquisition and integration have also burdened the group's results.

**Note 2**

**Peptonic Group**

	<b>30-sep 2022</b>	<b>30-sep 2021</b>	<b>31-dec 2021</b>
<b>Capitalized development costs</b>			
Accumulated acquisition value			
Opening balance	52 900	51 996	51 996
Sold out and Other disposals	0	0	0
Capitalizations during the period	138	904	904
	<b>53 038</b>	<b>52 900</b>	<b>52 900</b>
Accumulated depreciation value	-7 980	-5 171	-5 171
Deprecation of the year	-2 078	-1 855	-2 809
	<b>-10 058</b>	<b>-7 026</b>	<b>-7 980</b>
<b>Net booked amount at end of period</b>	<b>42 980</b>	<b>45 874</b>	<b>44 921</b>
<b>Patents och licenses</b>			
Accumulated acquisition value			
Opening balance	8 438	8 086	8 086
Sold out and Other disposals	0	0	0
Capitalizations during the period	407	248	352
	<b>8 845</b>	<b>8 334</b>	<b>8 438</b>
Depreciation			
Accumulated depreciation value	-1148	-841	-841
Deprecation of the year	-230	-230	-307
	<b>-1378</b>	<b>-1071</b>	<b>-1148</b>
<b>Net booked amount at end of period</b>	<b>7 467</b>	<b>7 263</b>	<b>7 290</b>
<b>Group goodwill</b>			
Accumulated acquisition values			
At the beginning of the period	23 495	23 495	23 495
Activations for the period	0	0	0
	<b>23 495</b>	<b>23 495</b>	<b>23 495</b>
Depreciation at the beginning of the period	-23 495	0	0
This year's depreciations	0	0	-23 495
Outgoing depreciation	-23 495	0	-23 495
<b>Net booked amount at end of period</b>	<b>0</b>	<b>23 495</b>	<b>0</b>
<b>Total intangible assets</b>	<b>50 447</b>	<b>76 632</b>	<b>52 210</b>

### Note 3 - Tangible fixed assets

#### Group

The Group has activated tools to produce products.

### Note 4 – Equity and liabilities

#### Group

There is SEK 16 022 thousand of interest-bearing debt in the Group.

#### KEY FIGURES

##### Peptonic Group

	9 mon jan-sep 2022	9 mon jan-sep 2021	12 mon jan-dec 2021	12 mon jan-dec 2020
Sales goods, KSEK	33 442	28 949	31 643	35 197
Gross profit sales goods, KSEK	19 002	16 060	19 070	21 138
Gross margin, %	57%	55%	60%	60%
Operating profit, KSEK	-26 807	-28 780	-73 718	-33 003
Return on equity,%	-212	-40	-87	-59
Equity ratio,%	63	87	62	86
Earnings per share, SEK	-0,12	-0,15	-0,38	-0,15
Liquidity per share, SEK	0,01	0,05	0,05	0,05
Equity per share, SEK	0,23	0,38	0,27	0,38
Share price per closing, SEK	0,33	0,97	0,63	1,73
Share price/Equity per share, SEK	1,42	2,57	2,30	4,58
Equity per share, SEK	<b>242 743 544</b>	<b>191 639 642</b>	<b>191 639 642</b>	<b>162 911 613</b>

## FINANSIELL INFORMATION

### Parent company Peptonic Medical AB

**Revenue** - Sales of goods during the third quarter amounted to SEK 1 024 (2 061) thousand. Other operating income for the quarter was SEK 0 (3) thousand.

During the first nine months of the year, sales of goods amounted to SEK 7 925 (6 541) thousand. Other operating income for the first nine months of the year was SEK 0 (-17) thousand.

**Costs** - Costs for the third quarter amounted to SEK -6 233 (-7 383) thousand. Costs of goods for the third quarter amounted to SEK -302 (-767) thousand.

Costs for the first the first nine months amounted to SEK -20 763 (-27 263) thousand. Costs of goods for the first nine months of the year amounted to SEK -3 609 (-2 961) thousand.

**Profit** - The company's profit after net financial items for the third quarter amounted to SEK -5 794 (-5 320) thousand. For the first nine months of the year the corresponding amount is SEK -14 672 (-20 795) thousand.

**Financial position and liquidity** - Cash and bank amounted to SEK 148 (7 656) thousand as of September 30th, 2022.

**Shareholders 'equity** - The group's shareholders' equity as of September 30, 2022, amounted to SEK 111 902 (110 439) thousand, which gives an equity / assets ratio of 89 (96) percent.

**Liabilities** - The group's liabilities, as of September 30, 2022, amounted to SEK 22 249 (3 777) thousand. Of which is KSEK 15 800 thousand interest-bearing liabilities.

**Organization** - During the period, the average number of employees was 3 (3). At the end of the period, the number of employees was 3 (3).

**Share** - The total number of shares as of September 30, 2022, was 242,743,544 (191,639,642).

**INCOME STATEMENT**

**Peptonic Medical AB**

KSEK	Note	3 mon jul-sep 2022	3 mon jul-sep 2021	9 mon jan-sep 2022	9 mon jan-sep 2021	12 mon jan-dec 2021
<b>Operating income</b>						
Sales of products		1 024	2 061	5 316	6 541	6 551
Intercompany sales		0	0	2 611	0	881
Other operating income		0	3	0	-17	130
<b>Total operating income</b>		<b>1 024</b>	<b>2 064</b>	<b>7 926</b>	<b>6 524</b>	<b>7 562</b>
<b>Operating expenses</b>						
Cost of goods		-302	-767	-3 609	-2 961	-3 151
Other external expenses	1	-2 991	-3 378	-9 751	-15 560	-23 903
Personnel costs		-2 221	-2 523	-5 188	-5 205	-11 569
Depreciation		-697	-695	-2 092	-2 085	-2 782
Other operating costs		-22	-20	-123	-1 452	-1 076
<b>Total operating expenses</b>		<b>-6 233</b>	<b>-7 383</b>	<b>-20 763</b>	<b>-27 263</b>	<b>-42 481</b>
<b>Operating loss</b>		<b>-5 209</b>	<b>-5 319</b>	<b>-12 836</b>	<b>-20 739</b>	<b>-34 919</b>
Net financial income/expense		-585	0	-1 836	-56	-10
<b>Loss before taxes</b>		<b>-5 794</b>	<b>-5 320</b>	<b>-14 672</b>	<b>-20 795</b>	<b>-34 928</b>
Taxes		0	0	0	0	0
<b>Net loss for the period</b>		<b>-5 794</b>	<b>-5 320</b>	<b>-14 672</b>	<b>-20 795</b>	<b>-34 928</b>

**BALANCE SHEET**

**Peptonic Medical AB**

KSEK	Note	30-sep 2022	30-sep 2021	31-dec 2021
<b>Assets</b>				
<b>Non-Current assets</b>				
Intangible assets	2	49 957	52 139	51 496
Tangible assets		39	49	46
Financial assets	3	53 450	43 369	53 450
<b>Total non-current assets</b>		<b>103 446</b>	<b>95 557</b>	<b>104 993</b>
<b>Current assets</b>				
Stock		3 172	2 485	2 060
On going fund raising		0	0	0
Other receivables		657	3 867	838
Group company receivables		25 934	4 300	8 199
Tax receivable		0	0	0
Prepaid expenses and accrued income		794	351	496
Liquid assets		148	7 656	2 849
<b>Total current assets</b>		<b>30 706</b>	<b>18 660</b>	<b>14 441</b>
<b>Total assets</b>		<b>134 152</b>	<b>114 216</b>	<b>119 434</b>
<b>Equity and liabilities</b>				
<b>Equity</b>				
<b>Restricted equity</b>				
Share capital		24 274	19 164	19 164
Ongoing right issues		0	0	0
Development Cost Fund		11 186	11 186	9 617
<b>Non- restricted equity</b>				
Share premium reserv non-restricted		272 044	249 662	248 439
Profit or loss brought forward		-180 930	-122 499	-146 002
Net loss for the period		-14 672	-47 074	-34 928
<b>Total equity</b>	3	<b>111 902</b>	<b>110 439</b>	<b>96 290</b>
<b>Current liabilities</b>				
Liabilities interest bearing		2 202	2 138	1 801
Trade payables		15 832	0	15 000
Other payables		371	345	652
Group company debts		0	0	0
Prepaid income and accrued expenses		3 845	1 294	5 691
<b>Total current liabilities</b>		<b>22 249</b>	<b>3 777</b>	<b>23 144</b>
<b>Total equity and liabilities</b>	4	<b>134 152</b>	<b>114 216</b>	<b>119 434</b>

## Note 1 – Related-party transactions

### Parentcompany Peptonic Medical AB

During the period companies represented by members of the Board of Directors were contracted as consultants. Total compensation for consultancy services amounted to SEK 513 (1 364) thousand and is related to business development services. All transactions between related parties are based on market conditions. No other key executives or their immediate family members have been directly or indirectly involved in any business transaction with the Company that is or was unusual in its character or terms and conditions and took place during the period.

KSEK	2022 Jan-Sep	2021 Jan-Sep	2020 Jan-Sep
Consulting fees Board of Directors	513	1364	665
<b>Total</b>	<b>513</b>	<b>1364</b>	<b>665</b>

## Note 2 – Intangible assets (KSEK)

Patent and development costs are capitalized and depreciated in 20 years from the first revenue that the group receives. The depreciations started in year 2019. Capitalized patent and development costs are estimated to result in future revenues for the Group. From 2019 they are depreciated at 5% per annum. Which corresponds to the estimated life of the commercial rights.

## Not 2

### Moderbolaget - Peptonic Medical AB

	30-sep 2022	30-sep 2021	31-dec 2021
<b>Balanserade utgifter för utvecklingsarbet</b>			
Akkumulerade anskaffningsvärden			
Vid periodens början	51 625	50 721	50 721
Försäljningar/utrangeringar	0	0	0
Periodens aktiveringar	138	904	904
	<b>51 763</b>	<b>51 625</b>	<b>51 625</b>
Avskrivningar vid periodens början	-7 419	-4 946	-4 946
Årets avskrivningar	-1 854	-1 855	-2 473
Utgående ack avskrivning	-9 273	-6 801	-7 419
	<b>42 490</b>	<b>44 825</b>	<b>44 206</b>
<b>Patent och licenser</b>			
Akkumulerade anskaffningsvärden			
Vid periodens början	8 438	8 086	8 086
Försäljningar/utrangeringar	0	0	0
Periodens aktiveringar	407	248	352
	<b>8 845</b>	<b>8 334</b>	<b>8 438</b>
Avskrivningar vid periodens början	-1148	-841	-841
Årets avskrivningar	-230	-230	-307
Utgående ack avskrivning	-1378	-1071	-1148
	<b>7 467</b>	<b>7 263</b>	<b>7 290</b>
<b>Totala immateriella anläggningstillgångar</b>	<b>49 957</b>	<b>52 088</b>	<b>51 496</b>

## Note 3 - Financial fixed assets

### Parentcompany

As of September 30, 2022, a total of SEK 53,450 thousand has been capitalized for the acquisition of subsidiaries.

## Note 4 – Equity and liabilities

### Parentcompany

There is SEK 15 832 thousand of interest-bearing debt in the company.



**This interim report has not been reviewed by the Company's auditors.**

The Board of Directors and the CEO certifies that the interim report gives a fair overview of the business, position and profit or loss of the Company.

**FINANCIAL CALENDER**

Year-end report, 2022	2023-02-24
-----------------------	------------

**Stockholm 10 nov, 2022**

Jan Bardell, Chairmen of the Board	Susanne Axelsson, Board member
------------------------------------	--------------------------------

Lena Munkhammar, Board member	Anders Norling, Board member
-------------------------------	------------------------------

Erik Sundquist, CEO

**For more information please contact:**

Erik Sundquist, CEO PEPTONIC medical AB. Phone: +46 722 499 043

*Note: This document has been prepared in both Swedish and English. The Swedish version shall govern in case of differences between the two documents. The document contains certain statements about the Company's operating environment and future performance. These statements should only be regarded as reflective of prevailing interpretations. No guarantees can be made that these statements are free from errors.*